Inhaled loxapine for the treatment of agitation in borderline personality disorder

Introduction Inhaled loxapine has shown efficiency in the treatment of the mild-moderate agitation syndrome of schyzophrenia and mania patients. Its rapid response and calming effect non-sedative allow to hypothesize reasonable efficiency and tolerability in borderline personality disorder diagnosed patients. Aims Analyze the efficiency and tolerability of inhaled loxapine as a pharmacological approach in the treatment of agitation in borderline personality disorder (BPD) clinical diagnosed patients. Materials and method An application was administered for every agitation episode in BPD patients treated with inhaled loxapine in the emergency room or the psychiatric ward, which included BARS and CGI-S scales for the evaluation of each episode and its severity, before and after its use. Other secondary measures of efficiency were taken into account, such as requirement of physical restrain. Results In the majority of evaluated episodes inhaled loxapine decreased notably initial BARS and CGI-S values and no serious clinical side effects attributable to this medication were observed. Conclusion In our sample, inhaled loxapine was efficiency and well tolerated pharmacological intervention for agitation in BPD patients.